Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization

Laboratory Investigation

Volumn 83, Issue 11, 2003, Pages 1637-1645

  Das, Arup ^a,b   Fanslow, William ^c   Cerretti, Douglas ^c   Warren, Erin ^a   Talarico, Nicholas ^a   McGuire, Paul ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; FC RECEPTOR; GELATINASE B; HYBRID PROTEIN; IMMUNOGLOBULIN G; MUTEK DELTA FC PROTEIN; OXYGEN; PROTEIN TEK; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HISTOLOGY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANIMALS, NEWBORN; CATTLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; IMMUNOGLOBULIN FC FRAGMENTS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, TIE-2; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; UP-REGULATION;

EID: 0242665386     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000097189.79233.D8     Document Type: Article

References (40)

1. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, and Yeo KT (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450.
2. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, and Miller JW (1996). Inhibition of vascular endothelial growth factor prevents ischemia-associated iris neovascularization. Arch Ophthalmol 114:66-71.
3. Aiello LP (1997). Vascular endothelial growth factor: 20th century mechanisms, 21st century therapies. Invest Ophthalmol Vis Sci 38:1647-1652.
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487.
5. Aiello LP, Northrup JM, Keyt BA, Takagi H, and Iwamoto MA (1995a). Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538-1544.
6. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, and Smith LE (1995b). Suppression of retinal neovascularization in vivo by inhibition of VEGF using a VEGF-receptor chimeric protein. Proc Natl Acad Sci USA 92:10457-10461.
7. Danis RP, Bingaman DP, Jirousek M, and Yang Y (1998). Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCb inhibition with LY333531. Invest Ophthalmol Vis Sci 39:171-179.
8. Das A, McGuire PG, Eriqat C, Ober RR, DeJuan E Jr, Williams GA, McLamore A, Biswas J, and Johnson DW (1999a). Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40:809-813.
9. Das A, McLamore A, Song W, and McGuire PG (1999b). Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117:498-503.
10. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, and Yancopoulos GD (1996). Isolation of angiopoietin-1, a ligand for the Tie-2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169.
11. Folkman J (1982). Angiogenesis: Initiation and control. Ann NY Acad Sci 401:212-227.
12. Folkman J (1986). How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46:467-473.
13. Friedlander M, Theesfeld C, and Sugita M (1996). Involvement of integrins αv/β3 and αv/β5 in ocular neovascular diseases. Proc Natl Acad Sci USA 93:9764-9769.
14. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, and Campochiaro PA (2000). Angiopoeitin-2 expression in the retina: Upregulation during physiologic and pathologic neovascularization. J Cell Physiol 184:275-284.
15. Hackett SF, Wiegand S, Yancopoulos G, and Campochiaro PA (2002). Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Phys 192:182-187.
16. Hangai M, Moon YS, Kitaya N, Chan CK, Wu DY, Peters KG, Ryan SJ, and Hinton DR (2001). Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum Gene Ther 12:1311-1321.
17. Johnson MR, Wang K, Smith JB, Heslin MJ, and Diasio RB (2000). Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278:175-184.
18. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, and Dumont DJ (1999). Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274:30896-30905.
19. Kwak HJM, So LN, Lee SJ, Kim I, and Koh GY (1999). Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448:249-253.
20. Loughna S and Sato TN (2001). Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 20:319-325.
21. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, and Yancopoulos GD (1997). Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277:55-60.
22. Majka SM, McGuire PG, Colombo SM, and Das A (2001). The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest Ophthalmol and Vis Sci 42:210-215.
23. Mignatti P and Rifkin DB (1996). Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme and Protein 49:117-137.
24. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al (1994). Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis. Am J Pathol 145:574-584.
25. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, and Honda Y (1999). Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274:15732-15739.
26. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, and Campochlaro PA (2000). Blockade of vascular endothelial growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156:697-707.
27. Ozaki H, Yu A, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, and Campochiaro PA (1999). Hypoxia-inducible factor-1a is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40:182-189.
28. Penn JS, Rajaratnam VS, Collier RC, and Clarke AF (2001). The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42:283-290.
29. Pepper MS and Montesano RP (1990). Proteolytic balance and capillary morphogenesis. Cell Differ Dev 32:319-327.
30. Pepper MS, Vassali JD, Wilks JW, Schweigerer L, Orci L, and Montesano R (1994). Modulation of microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 55:419-434.
31. Pierce EA, Avery RL, Foley ED, Aiello LP, and Smith LE (1995). Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905-909.
32. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, and Smith LE (1996). Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93:4851-4856.
33. Sato TN, Qin Y, Kozak CA, and Audus KL (1993). Tie-1 and Tie-2 define another class of putative receptor tyrosinase kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 90:9355-9358.
34. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, and Campochiaro PA (1999). Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154:1743-1753.
35. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, and Schaeffer JM (1997). Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706-1709.
36. Smith LE, Wesolowski E, McLellan, Kostyk SK, D'Amato R, Sullivan R, and D'Amore PA (1994). Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111.
37. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, and Yancopoulos GD (1996). Requisite role of Angiopoietin-1, a ligand for the Tie-2 receptor, during embryonic angiogenesis. Cell 87:1171-1180.
38. Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, and Honda Y (2003). Potential role of the angiopoietin/Tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 44:393-402.
39. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, and Stewart DJ (2001). Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie-2. Cardiovasc Res 49:659-670.
40. Werb Z, Vu TH, Rinkenberger JL, and Coussens LM (1999). Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107:11-18.